Chemoresistance factors in non-small cell lung cancer

Authors

  • А. I. Shevchenko Zaporizhzhia State Medical University,
  • А. P. Коlesnik Zaporizhzhia State Medical University,
  • А. V. Каdzhoian Zaporizhzhia State Medical University,
  • V. А. Кuzmenko Zaporizhzhia State Medical University,

DOI:

https://doi.org/10.14739/2310-1237.2016.1.71945

Keywords:

Non-Small Cell Lung Cancer, Chemotherapy, Chemoresistance

Abstract

Lung cancer takes the leading position in cancer morbidity and mortality structure in the world and Ukraine. Advanced stages are diagnosed in more than 70% of lung cancer patients. Chemotherapy remains the main method of treatment for advanced lung cancer. Currently, the standard of chemotherapy in patients with III–IV stages of non-small cell lung cancer (NSCLC) is a combination of cisplatin/carboplatin with paclitaxel, etoposide, gemcitabine and vinorelbine. Although, the objective response rate after chemotherapy treatment is only about 20–50%. Low rates of chemotherapy efficacy are connected with chemoresistance of tumor to definite chemotherapeutic agents. Tumor chemoresistance is the result of different tumor intracellular mechanisms activity. Basing on current data we tried to analyze prognostic and predictive value of main chemoresistance factors in NSCLC.

Conclusions. Nowadays we can certainly affirm that chemoresistance to cisplatin in NSCLC is due to increased expression of ERCC1 (Excision repair cross-complementation group 1 protein), BCRP; and resistance to taxanes is connected with elevated expression of β-tubuline III class; and tumoral chemoresistance to gemcitabine is due to high RRM1 (Ribinucleotide reductase M1) expression. High expression of BRCA1 (Breast Cancer 1) protein in tumors leads to increase of tumor cells resistance to cisplatin, but at the same time it increases the sensitivity to taxanes. Therefore, investigation of tumor chemoresistance plays an important role in algorithms’ creation for optimal chemotherapy schemes selection in patients with different stages of NSCLC in order to achieve the best tumor response to treatment and improve overall and disease-free survival. The information of main NSCLC chemoresistance factors, its prognostic and predictive value are presented in this overview.

References

Achiwa, H., Oguri, T., Sato, S., Maeda, H., Niimi, T., & Ueda, R. (2004). Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Science, 95(9), 753–757.

Bepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006). RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. Journal of Clinical Oncology, 24(29), 4731–4737.

Bepler, G., Sommers, K. E., Cantor, A., Li. X., Sharma, A., Williams, C., et al. (2008). Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. Journal of Thoracic Oncology, 3(10), 1112–1118. doi: 10.1097/JTO.0b013e3181874936.

Ceppi, P., Longo, M., Volante, M., Novello, S., Cappia, S., Bacillo, E., et al. (2008). Excision repair cross complementing-1 and topoisomerase II-alpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study. Journal of Thoracic Oncology, 3(6), 583–589. doi: 10.1097/JTO.0b013e3181734f24.

Chang, J. T., Chang, G. C., Ko, J. L., Liao, H. Y., Liu, H. J., Chen, C. C., et al. (2006). Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. International Journal of Cancer, 118(2), 317–325. doi: 10.1002/ijc.21372.

Chanvorachote, P., Nimmannit, U., Stehlik, C., Wang, L., Jiang, B. H., Ongpipatanakul, B., & Rojanasakul, Y. (2006). Nitric oxide regulates cell sensitivity to cisplatininduced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Research, 66(12), 6353–6360. doi: 10.1158/0008-5472.CAN-05-4533.

Chen, S., Jiang, M., & Zhen, Y. (2005). HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin. Cancer Chemotherapy and Pharmacology, 56(2), 212–220. doi: 10.1007/s00280-004-0960-5.

Cosse, J., & Michiels, C. (2008). Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anti-Cancer Agents in Medicinal Chemistry, 8(7), 790–797.

d'Amato, T. A., Landreneau, R. J., Ricketts, W., Huang, W., Parker, R., Mechetner, E., et al (2007). Chemotherapy resistance and oncogene expression in non-small cell lung. The Journal of Thoracic and Cardiovascular Surgery, 133(2), 352–363. doi:10.1016/j.jtcvs.2006.10.019.

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23(25), 5900– 5909. doi: 10.1200/JCO.2005.02.857.

Eyler, C., & Rich, J. (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. Journal of Clinical Oncology, 26(17), 2839–2845. doi: 10.1200/JCO.2007.15.1829.

Fujii, T., Toyooka, S., Ichimura, K., Fujiwara, Y., Hotta, K., Soh, J., et al. (2008). ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer. Lung Cancer, 59(3), 377–384. doi: 10.1016/j.lungcan.2007.08.025.

Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M.J. (2009). Cancer Statistics. CA: A Cancer Journal for Clinicians, 59(4), 225–249.

Ko, J. C., Ciou, S. C., Cheng, C. M., Wang, L. H., Hong, J. H., Jheng, M. Y., et al. (2008). Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, Iressa) and chemotherapeutic agents in human lung cancer cells. Carcinogenesis, 29(7), 1448–1458. doi: 10.1093/carcin/bgn130.

Krysan, K., Dalwadi, H., Sharma, S., Pold, M., & Dubinett, S. (2004). Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Research, 64(18), 6359–6362. doi: 10.1158/0008-5472.CAN-04-1681.

Meert, A. P., Martin, B., Paesmans, M., Berghmans, T., Mascaux, C., Verdebout, J. M., et al. (2003). The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. British Journal of Cancer, 89(6), 959–965. doi: 10.1038/sj.bjc.6601252.

Misawa, M., Tauchi, T., Sashida, G., Nakajima, A., Abe, K., Ohyashiki, J. H., & Ohyashiki, K. (2002). Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. International Journal of Oncology, 21(5), 1087–1092. doi: 10.3892/ijo.21.5.1087.

Oguri, T., Achiwa, H., Muramatsu, H., Ozasa, H., Sato, S., Shimizu, S., et al. (2007). The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in nonsmall cell lung cancer. Cancer Letters, 256(1), 112–119.

Peacock, C. D., & Watkins, D. N. (2008). Cancer stem cells and the ontogeny of lung cancer. Journal of Clinical Oncology, 26(17), 2883–2889. doi: 10.1200/JCO.2007.15.2702.

Rosell, R., Cuello, M., Cecere, F., Santarpia, M., Reguart, N., Felip, E., & Taron, M. (2006). Usefulness of predictive tests for cancer treatment. Bulletin du Cancer, 93(8), 101–108.

Salerno, M., Yahia, D., Dzamitika, S., de Vries, E., Pereira-Maia, E., & Garnier-Suillerot, A. (2009). Impact of intracellular chloride concentration on cisplatin accumulation in sensitive and resistant GLC4 cells. Journal of Biological Inorganic Chemistry, 14(1), 123–132. doi: 10.1007/s00775-008-0430-3.

Sartorius, U., & Krammer, P. (2002). Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. International Journal of Cancer, 97(5), 584–592. doi: 10.1002/ijc.10096.

Saviozzi, S., Ceppi, P., Novello, S., Ghio, P., Lo Iacono, M., Borasio, P., et al. (2009). Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Research, 69(80), 3390–3396. doi: 10.1158/0008-5472.CAN-08-2981.

Sève, P., Mackey, J. R., Isaac, S., Trédan, O., Souquet, P. J., Pérol, M., et al. (2005). cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer. Lung Cancer, 49(3), 363–370.

Shaw, G. L., Gazdar, A. F., Phelps, R., Steinberg, S. M., Linnoila, R. I., Johnson, B. E., et al. (1996). Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. Journal of cellular biochemistry, 24, 173–185. doi: 10.1002/jcb.240630513.

Shimura, M., Saito, A., Matsuyama, S., Sakuma, T., Terui, Y., Ueno, K., et al. (2005). Element array by scanning X-ray fluorescence microscopy after cis-diamminedichloro-platinum(II) treatment. Cancer Research, 65(12), 4998–5002.

Simon, G., Sharma,A., Li, X., Hazelton, T., Walsh, F., Williams, C., et al. (2007). Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. Journal of Clinical Oncology, 25(19), 2741–2746.

Socinski, M. A., Okamoto, I., Hon, J. K., Hirsh, V., Dakhil, S. R., Page, R. D., et al. (2013). Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Annals of Oncology, 24(9), 2390–2396. doi: 10.1093/annonc/mdt235.

Souglakos, J., Boukovinas, I., Taron, M., Mendez, P., Mavroudis, D., Tripaki, M., et al. (2008). Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/ gemcitabine. British Journal of Cancer, 98(10), 1710–1715. doi: 10.1038/sj.bjc.6604344.

Stewart, D. J., Tomiak, E., Shamji, F. M., Maziak, D. E., & MacLeod, P. (2004) Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer. Lung Cancer, 44(2), 241–249. doi: 10.1016/j.lungcan.2003.10.009.

Downloads

How to Cite

1.
Shevchenko АI, Коlesnik АP, Каdzhoian АV, Кuzmenko VА. Chemoresistance factors in non-small cell lung cancer. Pathologia [Internet]. 2016Jun.23 [cited 2024Apr.26];(1). Available from: http://pat.zsmu.edu.ua/article/view/71945

Issue

No. 1 (2016)

Section

Review

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Лицензия Creative Commons
    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  1. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).